Proton-Pump Inhibitors Therapy and Blood Pressure Control

Objective: To evaluate the potential impact of inhibitors of proton-pump in blood-pressure. .Methods: In a 24-hour-ambulatory-blood-pressure-monitoring (AMBP)-database we analyzed records of 462-hypertensive-patients according Proton-Pump Inhibitors (PPI). 150(33%)-patients were regularly users of PPI, and 312(67%) nonusers of PPI. Ambulatory-blood-pressure was measured non-invasively for 24--hours by the Spacelab-devices programmed-to-measure every 20-minutes during-daytime and every 60-minutes during-nighttime.Results: Systolic-blood-pressure(SBP) was lower in the Proton-Pump-Inhibitors (PPI)-group (13520.vs.13916mmHg, p=0,02) as well as diastolic-blood-pressure (DBP) (7610.vs.8310mmHg, p<0.001). Multivariate-analysis showed that use of beta-blocker(OR, 2.60) and PPI(OR, 2.70), were independently associated with blood-pressure-control.Conclusions: This study shows that concomitant PPI therapy in hypertensive-patients was associated with a small but statistically significant-reduction in 24-hours-BP, even after multivariate-adjustment. However, This statistical difference seems to lack clinical relevance.

[1]  F. Messerli,et al.  Drug-induced hypertension: an unappreciated cause of secondary hypertension. , 2012, The American journal of medicine.

[2]  Jerry Q. Cheng,et al.  Association between chlorthalidone treatment of systolic hypertension and long-term survival. , 2011, JAMA.

[3]  P. Souverein,et al.  Combined influence of proton‐pump inhibitors, calcium‐channel blockers and CYP2C19*2 on on‐treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention , 2011, Journal of thrombosis and haemostasis : JTH.

[4]  G. Triadafilopoulos,et al.  Adverse Effects of Long-Term Proton Pump Inhibitor Therapy , 2011, Digestive Diseases and Sciences.

[5]  Deepak L. Bhatt,et al.  Clopidogrel with or without omeprazole in coronary artery disease. , 2010, The New England journal of medicine.

[6]  F. Fuchs,et al.  Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects? , 2010, Expert review of cardiovascular therapy.

[7]  K. Murray,et al.  Outcomes With Concurrent Use of Clopidogrel and Proton-Pump Inhibitors , 2010, Annals of Internal Medicine.

[8]  J. Zamorano,et al.  Omeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma. , 2009, The Journal of allergy and clinical immunology.

[9]  M. Hanefeld,et al.  Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study) , 2008, Cardiovascular diabetology.

[10]  H. Blume,et al.  Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors , 2006, Drug safety.

[11]  E. Naseri,et al.  Proton pump inhibitors omeprazole and lansoprazole induce relaxation of isolated human arteries. , 2006, European journal of pharmacology.

[12]  Amy Roe,et al.  The Conduct of In Vitro and In Vivo Drug‐Drug Interaction Studies: A PhRMA Perspective , 2003, Journal of clinical pharmacology.

[13]  Y. Sarıoǧlu,et al.  Omeprazole-induced relaxation in rat aorta is partly dependent on endothelium. , 2002, Pharmacological research.

[14]  Jan A Staessen,et al.  Cardiovascular protection and blood pressure reduction: a meta-analysis , 2001, The Lancet.

[15]  S. Pocock,et al.  Identification of risk factors in hypertensive patients: contribution of randomized controlled trials through an individual patient database. , 1999, Circulation.

[16]  J. Douglas,et al.  H+-K+ ATPase inhibitors cause relaxation of guinea pig and human airway smooth muscle in vitro. , 1996, The Journal of pharmacology and experimental therapeutics.